BTIG Research Reaffirms "Buy" Rating for AC Immune

Analysts maintain positive outlook on biotech firm's stock despite recent volatility.

Mar. 16, 2026 at 12:19pm

Got story updates? Submit your updates here. ›

BTIG Research has reissued a "buy" rating and set a $8.00 price target on shares of AC Immune (NASDAQ:ACIU), a clinical-stage biopharmaceutical company focused on neurodegenerative diseases. This comes as several other equity research firms have also weighed in on the stock, with a mix of "buy", "hold", and "sell" ratings.

Why it matters

AC Immune's stock has seen significant price swings over the past year, reflecting the inherent volatility in the biotech sector. However, BTIG's continued endorsement of the company's prospects suggests analysts see long-term potential in AC Immune's pipeline of Alzheimer's and Parkinson's disease therapies.

The details

In its research report, BTIG maintained its "buy" rating and $8.00 price target on AC Immune, implying a potential upside of nearly 165% from the stock's current trading price around $3. The analysts cited the company's promising drug candidates and ongoing clinical trials as reasons for their positive outlook.

  • AC Immune's stock opened at $3.02 on Monday, March 16, 2026.
  • The company reported its latest quarterly earnings on Friday, March 13, 2026.

The players

AC Immune

A clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a focus on developing therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.

BTIG Research

An equity research firm that has maintained a "buy" rating on AC Immune's stock.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching AC Immune's future clinical trial results and regulatory updates as the company continues to advance its pipeline of Alzheimer's and Parkinson's disease therapies.

The takeaway

Despite recent stock price volatility, AC Immune maintains the support of at least one major research firm, BTIG, which sees significant upside potential in the company's neurodegenerative disease drug candidates. This highlights the high-risk, high-reward nature of investing in clinical-stage biotech firms.